Adagene Inc. ADAG
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +32.80%
- 1 year
- +30.73%
- Open
- 2.67
- Prev close
- 2.68
- Mkt cap
- 168.53M
- Vol
- 79.69K
- Avg vol
- 279.93K
- EPS
- -0.38
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.46
- High
- 2.69
- Forward P/E
- -2.81
- Beta
- 0.58
- Short ratio
- 0.66
- Inst. own
- 25.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 2, 2024
- 50-d avg
- 2.44
- 200-d avg
- 2.59
- 1y target
- 8.03
News
-
5 days ago benzinga.com
Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
5 days ago globenewswire.com
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte's TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
6 days ago globenewswire.com
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
-
1 month ago benzinga.com
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary…
-
1 month ago benzinga.com
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that…
-
1 month ago benzinga.com
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
-
2 months ago benzinga.com
Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 5.26 percent decrease over losses of $(0.19) per…
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
6 months ago benzinga.com
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%,…
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
Guggenheim Maintains Buy on Adagene, Raises Price Target to $10
Guggenheim analyst Paul Jeng maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $9 to $10.
-
7 months ago benzinga.com
Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases
Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement…
-
7 months ago benzinga.com
Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastasesStudy will be sponsored and conducted by Incyte; Adagene to provide…
-
7 months ago benzinga.com
Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 52.94 percent increase over losses of $(0.51) per…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31,…
-
11 months ago benzinga.com
Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Guggenheim analyst Paul Jeng initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDAPatients randomized to either 10 or 20 mg/kg of muzastotug,…
-
1 year ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Adagene, Lowers Price Target to $7
HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and lowers the price target from $8 to $7.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
Adagene H1 Adj. EPS $(0.19) Beats $(0.34) Estimate
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 26.92 percent increase over losses of $(0.26) per…
1 year ago benzinga.com
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
-
1 year ago benzinga.com
Leerink Partners Initiates Coverage On Adagene with Outperform Rating, Announces Price Target of $7
Leerink Partners analyst Daina Graybosch initiates coverage on Adagene (NASDAQ:ADAG) with a Outperform rating and announces Price Target of $7.
-
1 year ago benzinga.com
Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials
Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise…
-
2 years ago benzinga.com
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
2 years ago benzinga.com
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module.…
-
3 years ago benzinga.com
Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Vericity, Inc. (NASDAQ: VERY) shares climbed 87.4% to $11.12 after iA Financial Group announced it will acquire the company.
-
3 years ago benzinga.com
Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 120 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 269 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 216 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 198 companies made new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 368 stocks hit new 52-week lows.
-
4 years ago benzinga.com
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 88 companies set new 52-week lows.